Open an account

Tengion

TNGNQ · OTC

$0.00+$0.00 (+900.00%)TodayMarket closed ·
No price history for this range.

About TNGNQ

Tengion, Inc. is a medicine company, which engages in discovering, developing, manufacturing and commercializing neo-organs and products. The company is headquartered in Winston-Salem, North Carolina and currently employs 25 full-time employees. The company went IPO on 2010-04-09. The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient’s own cells. The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.

Employees
25
Headquarters
Winston-Salem, North Carolina
Listed
Apr 9, 2010
Sector
Health Care
Industry
Biotechnology
Website
tengion.com

TNGNQ key statistics

Market cap
402
Price-earnings ratio
-0.00
Dividend yield
—
Average volume
1.17K
Volume
1.06K
Open price
$0.00
High today
$0.00
Low today
$0.00
52 Week high
$0.0001
52 Week low
$0.00

Tengion (TNGNQ) at a glance

As of Aug 12, 2026, Tengion (TNGNQ) shares are priced at $0.00, giving the company a market cap of 402 and a price-to-earnings ratio of 0.00.

Volume so far is 1.06K shares, in line with the average of 1.17K shares a day.

Over the past year Tengion has ranged from $0.00 to $0.0001, and now sits 9% of the way up that range.

Tengion met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY12 it reported -$1.40 per share against an estimate of -$1.88.

TNGNQ earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 20.3% on average.

  1. Q3 FY10: reported -$5.40 per share against an estimate of -$5.66
  2. Q4 FY10: reported -$5.60 per share against an estimate of -$6.28
  3. Q1 FY11: reported -$4.10 per share against an estimate of -$4.38
  4. Q2 FY11: reported -$2.80 per share against an estimate of -$2.99
  5. Q3 FY11: reported -$0.40 per share against an estimate of -$2.78
  6. Q4 FY11: reported -$4.80 per share against an estimate of -$2.47
  7. Q1 FY12: reported -$2.10 per share against an estimate of -$2.16
  8. Q2 FY12: reported -$1.40 per share against an estimate of -$1.88

Similar companies

Companies in the same industry as Tengion

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.